AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

Background Patients with chronic kidney disease (CKD) have an increased risk of venous
thromboembolism (VTE) and atrial fibrillation (AF). Anticoagulants have not been studied in …

Background The prevalence of atrial fibrillation (AF) in individuals with end-stage renal
disease (ESRD) on chronic hemodialysis is increasing. The optimal anticoagulant choice in …

The most frequent arrhythmia treated is atrial fibrillation (AF), which necessitates the use of
oral anticoagulants (OACs) to reduce the risk of thromboembolism and stroke. Patients with …

Objective: A lack of clarity persists regarding the efficacy and risks associated with direct oral
anticoagulants (DOACs) in end-stage renal disease (ESRD) patients with atrial fibrillation …

Non‐vitamin K oral anticoagulants (NOACs) are used for prevention of thromboembolic
events, but their use in dialysis patients is debatable. This study investigated the available …

Objective: To evaluate the role of oral anticoagulation in patients with stage 5 chronic kidney
disease (CKD-5) or end-stage kidney disease (ESKD). Data Sources: A literature search of …

Background Nowadays, the number of patients with non-valvular atrial fibrillation (NVAF)
complicated by end-stage renal disease (ESKD) is increasing. There are significant …

Atrial fibrillation (AF) is common in patients with chronic kidney disease (CKD) undergoing
hemodialysis and in this patient population, management in terms of oral anticoagulation …

The prevalence of atrial fibrillation (AF) in patients with chronic kidney disease (CKD),
especially on hemodialysis (HD) is higher compared to the general population without CKD …